Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market

Cochlear Limited has announced the launch of the Nucleus Profile Plus Series Cochlear implant.

This is designed for routine 1.5 and 3 Tesla magnetic imaging scans without the need to remove it.

This means someone with the implant doesn’t need to remove the internal magnet when going for an MRI which makes the process easier and quicker.

Cochlear has also released the Nucleus 7 Sound Processor which is currently the first and only implant which can be controlled from a phone.

The Nucleus Profile Series also includes the thinnest implants in the world and a range of electrodes individually suited which will significantly impact hearing.

Currently, it is only available in Germany with other European countries expected to follow in the coming months and other developed markets expecting to launch after regularity approvals.

Please find announcement attached here

COH by the numbers
More From The Market Herald
Biogene Technology (ASX:BGT) - CEO, Richard Jagger

" Bio-Gene (ASX:BGT) shares close green on new commercial deal

Bio-Gene Technology (BGT) has executed a licence and development agreement with Evergreen Garden Care.
Beam Communications (ASX:BCC) - Chairman, Simon Wallace

" Beam Communications (ASX:BCC) receives orders for 12,000 ZOLEO units

Beam Communications (BCC) has received orders for 12,000 extra ZOLEO devices manufactured under its joint venture entity.
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

" Botanix Pharmaceuticals (ASX:BOT) progresses clinical programs

Botanix Pharmaceuticals (BOT) progressed a number of clinical programs during the September quarter.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham

" Recce Pharmaceuticals (ASX:RCE) receives ethics approval to begin R327 trial

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327).